Amyris Biotechnologies (NASDAQ: AMRS) is one of 25 public companies in the “Industrial organic chemicals” industry, but how does it contrast to its competitors? We will compare Amyris Biotechnologies to related businesses based on the strength of its analyst recommendations, earnings, valuation, risk, profitability, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Amyris Biotechnologies and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amyris Biotechnologies 0 1 2 0 2.67
Amyris Biotechnologies Competitors 121 483 748 27 2.49

Amyris Biotechnologies currently has a consensus target price of $9.67, indicating a potential upside of 46.24%. As a group, “Industrial organic chemicals” companies have a potential upside of 12.41%. Given Amyris Biotechnologies’ stronger consensus rating and higher possible upside, equities analysts clearly believe Amyris Biotechnologies is more favorable than its competitors.

Valuation and Earnings

This table compares Amyris Biotechnologies and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amyris Biotechnologies $143.45 million -$72.32 million -2.17
Amyris Biotechnologies Competitors $3.36 billion $346.16 million 3.96

Amyris Biotechnologies’ competitors have higher revenue and earnings than Amyris Biotechnologies. Amyris Biotechnologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Amyris Biotechnologies and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amyris Biotechnologies -53.95% N/A -89.90%
Amyris Biotechnologies Competitors -17.61% -14.04% -6.55%

Volatility & Risk

Amyris Biotechnologies has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Amyris Biotechnologies’ competitors have a beta of 0.49, indicating that their average stock price is 51% less volatile than the S&P 500.

Insider and Institutional Ownership

19.3% of Amyris Biotechnologies shares are held by institutional investors. Comparatively, 52.6% of shares of all “Industrial organic chemicals” companies are held by institutional investors. 11.3% of Amyris Biotechnologies shares are held by insiders. Comparatively, 14.2% of shares of all “Industrial organic chemicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Amyris Biotechnologies competitors beat Amyris Biotechnologies on 9 of the 13 factors compared.

Amyris Biotechnologies Company Profile

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive News & Ratings for Amyris Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Biotechnologies and related companies with's FREE daily email newsletter.